FDA removes the brakes on Pfizer and Lilly's pain drug
A once-halted pain candidate from partners Pfizer and Eli Lilly now has the green light to resume late-stage testing, as the FDA has lifted a clinical hold tied to some serious safety concerns for the whole class of drugs. The treatment, tanezumab, works by targeting nerve growth factor, a protein that regulates how the body processes pain.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063